A study presented during the 66th American Society of Hematology (ASH) Annual Meeting and Exposition reveals genetic factors that can affect the molecular pathways involved in ...
Syntara Limited (ASX:SNT), a clinical-stage drug development company, is pleased to announce positive interim data from its ongoing Phase 2 clinical trial evaluating SNT-5505 (200 mg BID) in ...
This dissertation investigates the risk and risk factors for new malignant and non-malignant neoplasms (SMNs and SNMNs) among childhood cancer survivors. In the Netherlands, the ‘Dutch Childhood ...
Younis, MA, Alsogaihi, MA, Abdellatif, AAH and Saleem, I Nanoformulations in the Treatment of Lung Cancer: Current Status and Clinical Potential. Drug Development and Industrial Pharmacy. ISSN ...